Key PointsThe prevalence of myeloid CHIP in patients with CLL was 12% in untreated and 24% in treated patients (85% with prior chemotherapy exposure).The p
Join the world’s leading hematology experts at Highlights of ASH in Asia-Pacific, a two-day program that highlights the most influential research presented at the latest…
Dear AHNS Members, As 2024 comes to a close, I am excited to share updates on our society’s progress over the last seven months…
The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.
Eighty-eight cents of every dollar you give does directly to cancer research. Cancer Research Saves Lives.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
PURPOSEThe use of anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CART) therapy for AL amyloidosis (AL) is limited owing to patient frailty. HBI0101 anti-BCMA…
Key Points+1q is associated with worse hematologic response rate and heme-EFS with daratumumab-based frontline therapy in AL amyloidosis.t(11;14) is no lon
Joe Leach, MD, discusses how comprehensive biomarker testing has impacted treatment selection for patients with small cell lung cancer.
Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
